MPQPPAK
MPQPPAK is a polypeptide obtained from the enzymatic hydrolysis of C-phycocyanin (HY-D1025) and possesses neuroprotective activity. MPQPPAK enhances the activities of antioxidant enzymes SOD, CAT, and GSH-Px, reduces ROS, inhibits apoptosis and acetylcholinesterase (AChE) activity in brain tissue, and decreases protein carbonyl content. In the MPTP (HY-W114750)-induced zebrafish Parkinson's disease model, MPQPPAK exhibits antioxidant effects, inhibits autophagy and apoptosis, reverses the loss of dopaminergic neurons and cerebral blood vessels, and alleviates motor deficits. MPQPPAK can be used for research on Parkinson's disease.
For research use only. We do not sell to patients.
- Formula: C34H57N9O9S
- Molecular Weight:767.94
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
AChE |
Caspase-1 |
Caspase-3 |
Caspase-8 |
Caspase-9 |
Bax |
In Vivo
MPQPPAK (5-320 μg/mL; bath immersion; daily; from 24 to 144 hpf) is safe in zebrafish embryos/larvae up to 160 μg/mL, with an LC50 of 177.744 μg/mL at 144 hpf[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:wild-type AB strain and transgenic vmat2:GFP and fli1:GFP strains (embryos/larvae at 24 hpf)[1]
-
Dosage:12.5, 25, 50 μg μg/mL
70 μM MPTP -
Administration:bath immersion; daily; from 96, 120, and 144 hpf
-
Result:Completely reversed MPTP-induced degeneration of DA neurons in a dose-dependent manner (MPTP alone reduced DA neuron region length by 19.16% on average).
Reversed the loss and disorganization of neural vasculature induced by MPTP.
Significantly increased the average movement speed and total distance traveled compared with the MPTP model group at high concentrations.
Reduced ROS levels, increased SOD, CAT, and GSH-Px activities, and decreased protein carbonyl content, with the highest concentration returning these to normal levels.
Inhibited MPTP-induced cell apoptosis in a concentration-dependent manner and inhibited AChE activity at moderate and high doses.
Upregulated oxidative stress-related genes (nrf2, gclc, gclm, ho-1, nqo-1), downregulated keap1, decreased autophagy-related genes (α-syn, parkin, beclin1, atg5, map1lc3b, atg3), and downregulated apoptosis-related genes (caspase-1, caspase-3, caspase-8, caspase-9, bax).
-
Animal Model:wild-type AB strain (embryos/larvae at 24 hpf)[1]
-
Dosage:5, 10, 20, 40, 80, 160, 320 μg μg/mL
-
Administration:bath immersion; daily; from 24, 48, 72, 96, 120, and 144 hpf
-
Result:Did not cause any toxicity or malformations in zebrafish embryos/larvae.
Exhibited LC1 and LC50 values of 63.322 μg/mL and 177.744 μg/mL, respectively, at 144 hpf.
Chemical Information
-
Molecular Weight 767.94
-
Formula C34H57N9O9S
-
Sequence
Met-Pro-Gln-Pro-Pro-Ala-Lys
-
Sequence Shortening
MPQPPAK
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MPQPPAK Related Classifications
HY-P12336 Related Classifications
Powered by Bioz
Keywords
- MPQPPAK
- Drug Derivative
- Cholinesterase (ChE)
- Reactive Oxygen Species (ROS)
- Caspase
- Keap1-Nrf2
- PINK1/Parkin
- Bcl-2 Family
- Autophagy
- Apoptosis
- acetylcholinesterase inhibitor
- Parkinson's disease
- MPTP
- Nrf2 signaling pathway activator
- apoptosis
- neural vasculature
- autophagy
- oxidative stress
- zebrafish
- dopaminergic neurons
- Inhibitor
- inhibitor
- inhibit